RLS-0071 is under clinical development by ReAlta Life Sciences and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RLS-0071’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RLS-0071 overview
ReAlta Life Sciences overview
ReAlta Life Sciences is a clinical stage biotech company. The company discovers, develops, novel therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes through its PIC1 technology platform. Its first target is complemented pathway and second target is inhibiting innate inflammatory processes. It’s product pipeline includes neurology, pulmonology, hematology for the treatment of hypoxic ischemic encephalopathy (HIE), acute lung injury and severe asthma, acute pulmonary exacerbations, chronic obstructive pulmonary disease (COPD), and platelet refractoriness. It also provides research and development services. ReAlta Life Sciences is headquartered in Norfolk, Virginia, the US.
For a complete picture of RLS-0071’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
